登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 2
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07739199,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Toxicities from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
入选标准第 8 条
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
入选标准第 7 条
Must have at least one measurable lesion as defined by RECIST v1.1;
入选标准第 6 条
Prior histological or cytological evidence of small cell lung cancer, neuroendocrine carcinoma, or carcinosarcoma components;
排除标准第 1 条
Diagnosis of active malignancy within 3 years before study randomization;
排除标准第 12 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07739199,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntarily sign the informed consent form and comply with the protocol requirements; Age ≥18 years; Expected survival time ≥3 months; Patients with locally advanced or metastatic squamous non-small cell lung cancer; Agree to provide tumor tissue samples obtained at or after the diagnosis of locally advanced or metastatic disease; Must have at least one measurable lesion as defined by RECIST v1.1; Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; Toxicities from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0; No severe cardiac dysfunction, with left ventricular ejection fraction ≥50%; Organ function levels must meet the specified requirements; Urinary protein ≤1+ or <1000 mg/24h; For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, with serum pregnancy test excluding pregnancy, and patients must be non-lactating; all enrolled patients (regardless of male or female) must take adequate barrier contraceptive measures throughout the entire treatment period and for 7 months after the end of treatment.排除标准:Exclusion Criteria:
Prior histological or cytological evidence of small cell lung cancer, neuroendocrine carcinoma, or carcinosarcoma components; Indications of the presence of EGFR-sensitive mutations, among others; Patients who have received prior systemic therapy; Prior treatment with agents targeting the mechanism of tumor immune action; Prior treatment with ADC drugs that use topoisomerase I inhibitors as the toxin, among others; Receipt of radical radiotherapy, major surgery, or large-field radiotherapy within 4 weeks before study randomization; History of severe heart disease or cerebrovascular disease; Receipt of long-term systemic corticosteroid therapy (e.g., prednisone >10 mg/day) before the first dose; Active autoimmune diseases and inflammatory diseases requiring systemic treatment within 2 years; Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Prolonged QTc interval, complete left bundle branch block, among others; Diagnosis of active malignancy within 3 years before study randomization; Hypertension inadequately controlled by two antihypertensive medications; Patients with poorly controlled blood glucose levels; History of ILD requiring steroid therapy, current ILD, or grade ≥2 radiation pneumonitis, among others; Pulmonary diseases leading to clinically severe impairment of respiratory function; Patients with active central nervous system metastases; Severe infection occurring within 4 weeks before study randomization; Presence of large serous cavity effusions or symptomatic serous cavity effusions, among others; Imaging findings indicating tumor invasion or encasement of the abdomen, chest, etc.; Severe non-healing wounds, ulcers, or fractures within 4 weeks before signing informed consent; Trial participants with clinically significant bleeding or a significant bleeding tendency within 4 weeks prior to signing informed consent; Patients with inflammatory bowel disease, history of extensive bowel resection, history of immune enteritis, intestinal obstruction, or chronic diarrhea, among others; History of allergy to recombinant humanized antibodies or hypersensitivity to any excipient of BL-B01D1; History of autologous or allogeneic stem cell transplantation; Positive for human immunodeficiency virus antibody, active hepatitis B virus infection, or hepatitis C virus infection; History of severe neurological or psychiatric disorders; Receipt of other unapproved clinical study drugs or treatments within 4 weeks before study randomization; Trial participants planning to receive or having received live vaccines within 28 days before study randomization; Other conditions deemed by the investigator as unsuitable for participation in this clinical trial due to complications or other circumstances.
引自 ClinicalTrials.gov, NCT07739199, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07739199,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。